We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

58 hedge funds and large institutions have $432M invested in LENZ Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.3% less ownership

Funds ownership: 8.85% → 8.54% (-0.3%)

3% less funds holding

Funds holding: 60 → 58 (-2)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

27% less capital invested

Capital invested by funds: $587M → $432M (-$156M)

Holders
58
Holders Change
-2
Holders Change %
-3.33%
% of All Funds
0.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
25
Reduced
11
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$8.15M
2
SB
Samsara BioCapital
California
+$4.97M
3
Morgan Stanley
Morgan Stanley
New York
+$3.37M
4
BlackRock
BlackRock
New York
+$3.11M
5
SFM
Sphera Funds Management
Israel
+$1.56M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$15.2M
2
DM
Deerfield Management
New York
-$14.9M
3
LGM
Logos Global Management
California
-$9.47M
4
Millennium Management
Millennium Management
New York
-$4.91M
5
Jennison Associates
Jennison Associates
New York
-$4.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$97.6M +$4.97M +60,045 +6%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$77.7M -$22.7K -274 -0%
RCM
3
RA Capital Management
Massachusetts
$33.5M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$25.8M +$26K +314 +0.1%
VA
5
VR Adviser
New York
$20M – – –
O
6
OrbiMed
New York
$19.5M +$1.37M +16,558 +8%
Citadel Advisors
7
Citadel Advisors
Florida
$15.5M -$295K -3,556 -2%
BlackRock
8
BlackRock
New York
$15.1M +$3.11M +37,479 +28%
Federated Hermes
9
Federated Hermes
Pennsylvania
$13.1M – – –
PA
10
Perceptive Advisors
New York
$10.6M -$296K -3,571 -3%
APM
11
Avidity Partners Management
Texas
$8.82M -$461K -5,570 -5%
BOTOTLSJU
12
Board of Trustees of The Leland Stanford Junior University
California
$8.74M – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$8.71M +$46.6K +563 +0.6%
AG
14
Artal Group
Luxembourg
$8.7M – – –
Morgan Stanley
15
Morgan Stanley
New York
$8.68M +$3.37M +40,660 +69%
EC
16
EcoR1 Capital
California
$8.56M +$8.15M +98,414 New
SFM
17
Sphera Funds Management
Israel
$8.24M +$1.56M +18,846 +25%
Norges Bank
18
Norges Bank
Norway
$6.89M – – –
LGM
19
Logos Global Management
California
$5.05M -$9.47M -114,286 -66%
OMC
20
OUP Management Company
Pennsylvania
$5.05M +$4.81M +58,044 New
WP
21
Woodline Partners
California
$3.73M – – –
Geode Capital Management
22
Geode Capital Management
Massachusetts
$3.35M +$140K +1,686 +5%
UBS AM
23
UBS AM
Illinois
$3.19M -$2.2M -26,568 -42%
State Street
24
State Street
Massachusetts
$3.19M +$708K +8,548 +30%
CAM
25
Cormorant Asset Management
Massachusetts
$2.52M – – –
1
2 3

LENZ Hedge Fund Activity: Q4 2021 in Review

58 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2021, worth a combined $432M — down 27% from $587M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of LENZ and 9 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 25 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $8.15M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $15.2M sold.

  • 58 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2021, down from 60 in Q3 2021.
  • Funds reported $432M of LENZ Therapeutics stock for Q4 2021, down 27% quarter-over-quarter.
  • 9 funds opened new LENZ Therapeutics positions in Q4 2021 and 11 closed out, a net change of -2 holders.
  • The largest LENZ Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $8.15M added.
  • The largest LENZ Therapeutics seller in Q4 2021 was Janus Henderson Group, an estimated $15.2M sold.

Based on aggregated 13F filings for Q4 2021.